XBIO
Xenetic Biosciences Inc
Price:  
2.89 
USD
Volume:  
2,759.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

XBIO WACC - Weighted Average Cost of Capital

The WACC of Xenetic Biosciences Inc (XBIO) is 5.6%.

The Cost of Equity of Xenetic Biosciences Inc (XBIO) is 7.55%.
The Cost of Debt of Xenetic Biosciences Inc (XBIO) is 5.00%.

Range Selected
Cost of equity 6.60% - 8.50% 7.55%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 5.00% - 5.00% 5.00%
WACC 5.1% - 6.1% 5.6%
WACC

XBIO WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.59 0.65
Additional risk adjustments 0.0% 0.5%
Cost of equity 6.60% 8.50%
Tax rate 26.20% 27.00%
Debt/Equity ratio 1 1
Cost of debt 5.00% 5.00%
After-tax WACC 5.1% 6.1%
Selected WACC 5.6%

XBIO's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for XBIO:

cost_of_equity (7.55%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.59) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.